Research programme: serotonin 6 receptor antagonists - AbbVie
Alternative Names: A-964324Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Abbott Laboratories
- Class
- Mechanism of Action Serotonin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Schizophrenia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Schizophrenia in USA
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie